JP2013529645A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529645A5 JP2013529645A5 JP2013516830A JP2013516830A JP2013529645A5 JP 2013529645 A5 JP2013529645 A5 JP 2013529645A5 JP 2013516830 A JP2013516830 A JP 2013516830A JP 2013516830 A JP2013516830 A JP 2013516830A JP 2013529645 A5 JP2013529645 A5 JP 2013529645A5
- Authority
- JP
- Japan
- Prior art keywords
- heteroaralkyl
- amine
- aralkyl
- heteroaryl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 heteroaryloxyl Chemical group 0.000 claims description 62
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 32
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 32
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000003342 alkenyl group Chemical group 0.000 claims description 26
- 125000000304 alkynyl group Chemical group 0.000 claims description 26
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- 150000001412 amines Chemical class 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 24
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 150000002431 hydrogen Chemical group 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 17
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000004104 aryloxy group Chemical group 0.000 claims description 13
- 125000002252 acyl group Chemical group 0.000 claims description 12
- 125000004423 acyloxy group Chemical group 0.000 claims description 12
- 125000005035 acylthio group Chemical group 0.000 claims description 12
- 125000003302 alkenyloxy group Chemical group 0.000 claims description 12
- 125000005137 alkenylsulfonyl group Chemical group 0.000 claims description 12
- 125000005108 alkenylthio group Chemical group 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- 150000003973 alkyl amines Chemical class 0.000 claims description 12
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 12
- 125000004414 alkyl thio group Chemical group 0.000 claims description 12
- 125000005133 alkynyloxy group Chemical group 0.000 claims description 12
- 125000005139 alkynylsulfonyl group Chemical group 0.000 claims description 12
- 125000005109 alkynylthio group Chemical group 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 12
- 150000003974 aralkylamines Chemical class 0.000 claims description 12
- 125000005140 aralkylsulfonyl group Chemical group 0.000 claims description 12
- 150000004982 aromatic amines Chemical class 0.000 claims description 12
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 12
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 12
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 12
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 12
- 125000005110 aryl thio group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 12
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 12
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 12
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims description 12
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 12
- LBQAJLBSGOBDQF-UHFFFAOYSA-N nitro azanylidynemethanesulfonate Chemical compound [O-][N+](=O)OS(=O)(=O)C#N LBQAJLBSGOBDQF-UHFFFAOYSA-N 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 229920005862 polyol Polymers 0.000 claims description 10
- 150000003077 polyols Chemical class 0.000 claims description 10
- 229920006295 polythiol Polymers 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000006413 ring segment Chemical group 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 150000006636 nicotinic acid Chemical class 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 12
- 210000002966 serum Anatomy 0.000 claims 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 9
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 6
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 6
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 6
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims 4
- 108010082126 Alanine transaminase Proteins 0.000 claims 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 4
- 239000011664 nicotinic acid Substances 0.000 claims 4
- 229960003512 nicotinic acid Drugs 0.000 claims 4
- 235000001968 nicotinic acid Nutrition 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 3
- 108010028554 LDL Cholesterol Proteins 0.000 claims 3
- 108010033266 Lipoprotein(a) Proteins 0.000 claims 3
- 102000057248 Lipoprotein(a) Human genes 0.000 claims 3
- 235000012000 cholesterol Nutrition 0.000 claims 3
- 238000011010 flushing procedure Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010007270 Carcinoid syndrome Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 101000843809 Homo sapiens Hydroxycarboxylic acid receptor 2 Proteins 0.000 claims 2
- 102100030643 Hydroxycarboxylic acid receptor 2 Human genes 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010029400 Nicotinic acid deficiency Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000002141 Pellagra Diseases 0.000 claims 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims 2
- 206010047139 Vasoconstriction Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 102000000072 beta-Arrestins Human genes 0.000 claims 2
- 108010080367 beta-Arrestins Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000010706 fatty liver disease Diseases 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 2
- 208000003532 hypothyroidism Diseases 0.000 claims 2
- 230000002989 hypothyroidism Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 208000006132 lipodystrophy Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010044008 tonsillitis Diseases 0.000 claims 2
- 229940116269 uric acid Drugs 0.000 claims 2
- 230000025033 vasoconstriction Effects 0.000 claims 2
- 230000024883 vasodilation Effects 0.000 claims 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 1
- 206010019837 Hepatocellular injury Diseases 0.000 claims 1
- 206010019851 Hepatotoxicity Diseases 0.000 claims 1
- 208000005736 Nervous System Malformations Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 231100000437 hepatocellular injury Toxicity 0.000 claims 1
- 231100000304 hepatotoxicity Toxicity 0.000 claims 1
- 230000007686 hepatotoxicity Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- 0 *C(*)(c1c(*)c(*)c(*)c(*)n1)N1CCCC*CCCCC1 Chemical compound *C(*)(c1c(*)c(*)c(*)c(*)n1)N1CCCC*CCCCC1 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35824510P | 2010-06-24 | 2010-06-24 | |
| US61/358,245 | 2010-06-24 | ||
| PCT/US2011/041869 WO2011163612A1 (en) | 2010-06-24 | 2011-06-24 | Niacin mimetics, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013529645A JP2013529645A (ja) | 2013-07-22 |
| JP2013529645A5 true JP2013529645A5 (enExample) | 2014-08-07 |
| JP5925770B2 JP5925770B2 (ja) | 2016-05-25 |
Family
ID=45371840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013516830A Expired - Fee Related JP5925770B2 (ja) | 2010-06-24 | 2011-06-24 | ナイアシン模倣体、およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8937063B2 (enExample) |
| EP (1) | EP2584899B1 (enExample) |
| JP (1) | JP5925770B2 (enExample) |
| AU (1) | AU2011270719B2 (enExample) |
| CA (1) | CA2802945A1 (enExample) |
| WO (1) | WO2011163612A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5925771B2 (ja) * | 2010-06-24 | 2016-05-25 | トラスティーズ オブ タフツ カレッジ | ナイアシン模倣体、およびその使用方法 |
| KR102194745B1 (ko) | 2013-03-13 | 2020-12-24 | 포르마 세라퓨틱스 인크. | Ｆａｓｎ 억제용 신규 화합물 및 조성물 |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| MX2015014666A (es) | 2013-04-17 | 2016-03-01 | Pfizer | Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares. |
| WO2016077832A2 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS |
| KR20180073597A (ko) * | 2015-11-06 | 2018-07-02 | 젬파이어 세러퓨틱스 인코포레이티드 | 혼합 이상지질혈증의 치료 |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| EP3873214A4 (en) | 2018-10-29 | 2022-07-13 | Forma Therapeutics, Inc. | Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
| US11633554B1 (en) * | 2019-06-11 | 2023-04-25 | Luca Puviani | Adaptive systems and methods for delivery of a medicament |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
| US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
| US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
| US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
| US4021436A (en) | 1974-03-15 | 1977-05-03 | Claudio Cavazza | Derivatives of nicotinic acid with amines variously substituted |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4503223A (en) | 1983-08-11 | 1985-03-05 | Usv Pharmaceutical Corporation | Process for the purification of N-morpholinoalkyl dihydropyridines |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| EP2319513A1 (en) | 1993-09-20 | 2011-05-11 | Abbott Respiratory LLC | Nicotinic acid compositons for treating hyperlipidemia and related methods therefor |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| US6603000B2 (en) | 2001-07-11 | 2003-08-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Synthesis for heteroarylamine compounds |
| EP1636187A1 (en) * | 2003-06-12 | 2006-03-22 | Novo Nordisk A/S | Substituted piperazine carbamates for use as inhibitors of hormone sensitive lipase |
| JP2008519080A (ja) * | 2004-11-05 | 2008-06-05 | アリーナ ファーマシューティカルズ， インコーポレイテッド | ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物 |
| US20070105793A1 (en) * | 2005-11-04 | 2007-05-10 | Curt Hendrix | Compositions and methods using nicotinic acid for treatment of hypercholesterolemia, hyperlipidemia nd cardiovascular disease |
| CA2659747C (en) * | 2006-08-03 | 2015-09-08 | Trustees Of Tufts College | Non-flushing niacin analogues, and methods of use thereof |
| AU2008219599A1 (en) | 2007-03-01 | 2008-09-04 | Concourse Health Sciences Llc | Isomers of inositol niacinate and uses thereof |
| MX2011004553A (es) | 2008-10-29 | 2011-07-20 | Sirtris Pharmaceuticals Inc | Piridina, piridina biciclica y analogos relacionados como moduladores de sirtuina. |
| WO2010065549A1 (en) * | 2008-12-01 | 2010-06-10 | Paul Slowey | Multi compartment body part scraping fluid collection device |
| JP5925771B2 (ja) * | 2010-06-24 | 2016-05-25 | トラスティーズ オブ タフツ カレッジ | ナイアシン模倣体、およびその使用方法 |
-
2011
- 2011-06-24 JP JP2013516830A patent/JP5925770B2/ja not_active Expired - Fee Related
- 2011-06-24 US US13/168,629 patent/US8937063B2/en not_active Expired - Fee Related
- 2011-06-24 WO PCT/US2011/041869 patent/WO2011163612A1/en not_active Ceased
- 2011-06-24 AU AU2011270719A patent/AU2011270719B2/en not_active Ceased
- 2011-06-24 EP EP11799002.8A patent/EP2584899B1/en not_active Not-in-force
- 2011-06-24 CA CA2802945A patent/CA2802945A1/en not_active Abandoned
-
2014
- 2014-12-10 US US14/566,343 patent/US20150094303A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529645A5 (enExample) | ||
| CN103096895B (zh) | 烟酸模拟物及其使用的方法 | |
| AU2011270719B2 (en) | Niacin mimetics, and methods of use thereof | |
| CN110025608A (zh) | 降低心血管疾病风险的方法 | |
| JP2014193913A (ja) | 安定化されたカリスバメートの小児用懸濁液 | |
| RU2005107416A (ru) | Эйкозапентаеновая кислота (эпк) для лечения нервно-психической анорексии (на) и булимии | |
| JP2020516622A (ja) | ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法 | |
| JP2008513417A (ja) | ロフルミラスト又はロフルミラストのｎ−オキシドを含有する医薬組成物 | |
| TW200812592A (en) | Use of strobilurins for the treatment of disorders of iron metabolism | |
| JP6761347B2 (ja) | 脂質異常症治療剤 | |
| JP6153264B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 | |
| JP5997658B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 | |
| JP2018197273A (ja) | 脂質異常症治療剤 | |
| JP2017095428A (ja) | 脂質代謝改善剤 | |
| JP7418502B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 | |
| CN104869988B (zh) | 3‑羧基‑n‑乙基‑n,n‑二甲基丙‑1‑铵或其药学上可接受的盐在治疗动脉粥样硬化中的用途 | |
| JP2005060311A (ja) | Ｎ−（ベンゾイル）アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤 | |
| AU2015203711A1 (en) | Niacin mimetics, and methods of use thereof | |
| WO2018092765A1 (ja) | 経鼻投与用医薬組成物 |